Form 4: RA Capital Management Director Equity Grant at Janux

RA Capital Management reports a grant of restricted stock units and stock options to Dr. Jake Simson for his service on the Janux Therapeutics board.

Summary

• Dr. Jake Simson, a partner at RA Capital Management, received a grant of 5,500 restricted stock units (RSUs) on June 11, 2026.
• Dr. Simson was also granted a stock option to purchase 15,500 shares of common stock at an exercise price of $13.66.
• The RSUs vest on the earlier of June 11, 2027, or the date of the next annual stockholder meeting.
• The stock options vest in equal monthly installments over 12 months, with full vesting by the next annual meeting.
• The securities are held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. to offset advisory fees.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation and does not signal a change in company strategy or financial health.

Positives

• Alignment of interests between board members and shareholders through equity-based compensation.
• Clear vesting schedules ensure long-term commitment from the director.

Negatives

• Dilutive impact of new equity grants on existing shareholders, though the amount is relatively small.

Risks

• Continued service requirement for vesting of both RSUs and stock options.
• Market price volatility affecting the value of the granted options.

Future Outlook

The equity grants are subject to continuous service requirements, incentivizing the director to remain with the company through at least the next annual meeting.

Management Comments

• The reporting persons disclaim beneficial ownership of the options and RSUs, as they are held for the benefit of the associated investment funds.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is standard practice in the biotechnology sector to align director incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The use of RSUs and stock options for board compensation is consistent with standard corporate governance practices for mid-cap biotech firms.
• The vesting period of one year is typical for annual director equity grants.

Corporate Governance

Related Party Transactions

• The director holds the equity for the benefit of RA Capital Management funds to offset advisory fees.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of RSUs on June 11, 2027, or the next annual meeting.
• Monthly vesting of stock options over the next 12 months.

Key Dates

Keywords

Janux Therapeutics, JANX, RA Capital Management, Form 4, Director Compensation, Equity Grant, Insider Ownership